Rectal plasmablastic lymphoma in Ebstein Barr virus positive and human immunodeficiency virus negative subject after external radiation therapy for prostatic cancer

L Bricman; P Yengue; C Miscu; S Junius; F Waignein; J-M Vandenbulcke

doi:10.51821/84.4.018

Rectal plasmablastic lymphoma in Ebstein Barr virus positive and human immunodeficiency virus negative subject after external radiation therapy for prostatic cancer

Acta Gastroenterol Belg. 2021 Oct-Dec;84(4):663-665. doi: 10.51821/84.4.018.

Authors

L Bricman¹, P Yengue¹, C Miscu¹, S Junius², F Waignein³, J-M Vandenbulcke⁴

Affiliations

¹ Department of Gastroenterology, Centre Hospitalier de Wallonie Picarde, Tournai, Belgium.
² Department of Radiotherapy, Centre Hospitalier de Mouscron, Belgium.
³ Department of Anatomopathology, Centre Hospitalier de Wallonie Picarde, Tournai, Belgium.
⁴ Department of Oncology, Centre Hospitalier de Wallonie Picarde, Tournai, Belgium.

PMID: 34965049
DOI: 10.51821/84.4.018

Abstract

Plasmablastic lymphoma (PBL) represents a rare and aggressive subtype of diffuse large B cells lymphoma (DLBCL) most associated with the human immunodeficiency virus (HIV). Prognosis remains poor despite various treatment approaches. We describe an evolution at six months of HIV negative PBL and Ebstein Barr virus (EBV) positive PBL with chemotherapy. Role of radiotherapy is still unclear.

Keywords: Ebstein Barr virus; chemotherapy; external radiotherapy; plasmablastic lymphoma; rectal bleeding.

Publication types

Case Reports

MeSH terms

Epstein-Barr Virus Infections*
HIV
Herpesvirus 4, Human
Humans
Male
Plasmablastic Lymphoma* / diagnosis
Plasmablastic Lymphoma* / etiology
Prostatic Neoplasms*